image_credit_united_states_mission_geneva

WHO leaves breakthrough cancer therapies off updated Essential Medicines List

pharmafile | July 10, 2019 | News story | Research and Development Cancer, EML, WHO, essential medicines list, oncology, pharma, world health organization 

The World Health Organization (WHO) has updated its list of essential medicines to include 28 more drugs.

The WHO’s Essential Medicine List (EML) has been updated to include 28 new medicines including five cancer therapies.

However a number of breakthrough cancer therapies have been left of the updated list including Merck’s Keytruda, Roche’s Tencentriq and Bristol-Myers Squibb’s Opdivo.

“The Committee considered that their place in therapy for this condition is still evolving and that more data with longer follow-up are needed to better demonstrate estimates of their actual magnitude of benefit,” the WHO said.

Roche commented: “We are disappointed that, on this occasion, our checkpoint inhibitor Tecentriq is not included in the EML.”

Additionally, the WHO put abortion pill mifepristone on its core list of essential medicines. However the WHO noted that the drug should only be used “where permitted under national law and where culturally acceptable.”

The new list also includes three new antibiotics, new oral anticoagulants, a number of new biologics for rheumatoid arthritis and inflammatory bowel disease, and oxytocin-analogue carbetocin for the prevention of postpartum haemorrhage. Sanofi’s Dengue vaccine Dengvaxia also features on the WHO’s updated list.

Louis Goss

Related Content

Scientists use AI to find new antibiotic to fight superbug

Scientists at McMaster University and the Massachusetts Institute of Technology (MIT) have utilised artificial intelligence …

volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …

national-cancer-institute-kmvohcb-w5g-unsplash_1

AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

Latest content